Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
International Vaccine Institute
The International Vaccine Institute (IVI) is a non-profit, autonomous international organization established with the mandate of making vaccines available to all. Collaborating closely with the global scientific community, public health entities, governments, and industry stakeholders, IVI focuses on vaccine research and deployment. This includes conducting new vaccine designs in laboratories, advancing vaccine development and assessment in real-world settings, and facilitating the sustainable integration of vaccines in regions where they are most urgently required.
Initially conceived as an initiative under the auspices of the United Nations Development Program (UNDP), IVI transitioned into a fully-independent international entity in 1997, with its headquarters situated in Seoul, Republic of Korea. IVI currently has a membership comprising 39 states, with 33 signatories and 23 parties, alongside the endorsement of the World Health Organization (WHO) through its Establishment Agreement. Distinctively, IVI is mandated to concentrate exclusively on vaccine research and deployment tailored to populations in developing areas, with particular emphasis on combating diseases with a serious impact on public health in these regions.
In 1992, Dr. Seung-Il Shin, then Senior Health Advisor for the United Nations Development Program (UNDP), initiated a study to explore the feasibility of establishing an international institute devoted to vaccine research and development within the framework of the Children's Vaccine Initiative (CVI).
Based on the results of Shin's feasibility study, the UNDP adopted a formal proposal to establish the International Vaccine Institute (IVI) in 1993. In 1994, following a call for proposals to host IVI in the Asia Pacific region, the UNDP and the Republic of Korea reached an agreement to host the center in Seoul. In 1995, UNDP opened an interim IVI office on the campus of Seoul National University, and the Institute began its initial work and organizational development.
In 1995 and 1996, the UNDP and the South Korean government jointly developed the basic framework and Constitution of IVI. In order to establish IVI as an independent international organization, the UNDP and Korean government elected to establish the institute through an intergovernmental agreement of UN member states, as sanctioned in the Vienna Convention on the Laws of Treaties of 1969.
On October 28, 1996, the IVI Establishment Agreement opened for signatures at the UN headquarters in New York City. Representatives from Bangladesh, Bhutan, Indonesia, Kazakhstan, Mongolia, the Netherlands, Panama, Republic of Korea, Romania, Thailand, Vietnam, Uzbekistan, and the World Health Organization were the first to sign the agreement, followed shortly thereafter by Senegal and Philippines.
In 1997, more countries followed, with Brazil, China, Egypt, Israel, Jamaica, Kyrgyzstan, Myanmar, Nepal, Pakistan, Papua New Guinea, Peru, Sri Lanka, Sweden, Tajikistan, and Turkey signing the Agreement.
On May 29, 1997, The IVI Establishment Agreement entered into force following the submission of instruments of ratification by South Korea, Sweden, and Uzbekistan. The IVI Establishment Agreement entered the United Nations Depository of Treaties under Chapter IX. HEALTH, section 3.
Hub AI
International Vaccine Institute AI simulator
(@International Vaccine Institute_simulator)
International Vaccine Institute
The International Vaccine Institute (IVI) is a non-profit, autonomous international organization established with the mandate of making vaccines available to all. Collaborating closely with the global scientific community, public health entities, governments, and industry stakeholders, IVI focuses on vaccine research and deployment. This includes conducting new vaccine designs in laboratories, advancing vaccine development and assessment in real-world settings, and facilitating the sustainable integration of vaccines in regions where they are most urgently required.
Initially conceived as an initiative under the auspices of the United Nations Development Program (UNDP), IVI transitioned into a fully-independent international entity in 1997, with its headquarters situated in Seoul, Republic of Korea. IVI currently has a membership comprising 39 states, with 33 signatories and 23 parties, alongside the endorsement of the World Health Organization (WHO) through its Establishment Agreement. Distinctively, IVI is mandated to concentrate exclusively on vaccine research and deployment tailored to populations in developing areas, with particular emphasis on combating diseases with a serious impact on public health in these regions.
In 1992, Dr. Seung-Il Shin, then Senior Health Advisor for the United Nations Development Program (UNDP), initiated a study to explore the feasibility of establishing an international institute devoted to vaccine research and development within the framework of the Children's Vaccine Initiative (CVI).
Based on the results of Shin's feasibility study, the UNDP adopted a formal proposal to establish the International Vaccine Institute (IVI) in 1993. In 1994, following a call for proposals to host IVI in the Asia Pacific region, the UNDP and the Republic of Korea reached an agreement to host the center in Seoul. In 1995, UNDP opened an interim IVI office on the campus of Seoul National University, and the Institute began its initial work and organizational development.
In 1995 and 1996, the UNDP and the South Korean government jointly developed the basic framework and Constitution of IVI. In order to establish IVI as an independent international organization, the UNDP and Korean government elected to establish the institute through an intergovernmental agreement of UN member states, as sanctioned in the Vienna Convention on the Laws of Treaties of 1969.
On October 28, 1996, the IVI Establishment Agreement opened for signatures at the UN headquarters in New York City. Representatives from Bangladesh, Bhutan, Indonesia, Kazakhstan, Mongolia, the Netherlands, Panama, Republic of Korea, Romania, Thailand, Vietnam, Uzbekistan, and the World Health Organization were the first to sign the agreement, followed shortly thereafter by Senegal and Philippines.
In 1997, more countries followed, with Brazil, China, Egypt, Israel, Jamaica, Kyrgyzstan, Myanmar, Nepal, Pakistan, Papua New Guinea, Peru, Sri Lanka, Sweden, Tajikistan, and Turkey signing the Agreement.
On May 29, 1997, The IVI Establishment Agreement entered into force following the submission of instruments of ratification by South Korea, Sweden, and Uzbekistan. The IVI Establishment Agreement entered the United Nations Depository of Treaties under Chapter IX. HEALTH, section 3.